Voyager Therapeutics Inc (VYGR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Voyager Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 3.00 $ — 0% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 12.3%
- Exp. sales growth 3Y > 5% 19.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 19.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 2
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -61.1%
- ROCE > 15% -58.4%
- Expected return > 10% -66.9%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -0.4% failed
- More than 10% revenue growth is expected for the coming year 41.7% passed
- Share count grows by less than 3% a year 15.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -384.1% failed
- Gross margin at 40% or higher and without meaningful erosion -227.6% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 160 m net cash passed
- Operating cash flow covers the profits of the last three years -17 m failed
- Return on capital at 15% or higher, or up versus two years ago -58.4% failed
- Insiders hold at least 10% or are net buyers 15.1% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 396.3% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.66 | -2.17 – -0.71 | 39 | 18.8% | 8 |
| 12/31/2027 | -1.56 | -2.59 – -0.53 | 57 | 5.9% | 9 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.55 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.59 | -147.50 | 6 | -93.00 | -549.30 | -15 | -15 |
| 2025: Q1 | -0.53 | – | 7 | -66.80 | -479.20 | -38 | -39 |
| 2025: Q2 | -0.57 | – | 5 | -82.40 | -642.00 | -33 | -34 |
| 2025: Q3 | -0.47 | – | 13 | -45.70 | -208.70 | -31 | -31 |
| 2025: Q4 | -0.47 | – | 15 | 144.30 | -178.80 | -30 | -31 |
| 2026: Q1 | -0.47 | – | 3 | -59.90 | -1,077.40 | -33 | -33 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 14 | -41 | -40 | -1.59 | -42 | 136 | 190 |
| 2017 | 10 | -72 | -71 | -2.64 | -61 | 134 | 184 |
| 2018 | 8 | -91 | -88 | -2.75 | -16 | 46 | 177 |
| 2019 | 104 | -52 | -41 | -1.14 | 49 | 100 | 355 |
| 2020 | 171 | 27 | 37 | 0.98 | -97 | 154 | 262 |
| 2021 | 37 | -74 | -66 | -1.75 | -54 | 95 | 194 |
| 2022 | 41 | -51 | -46 | -1.21 | -13 | 59 | 159 |
| 2023 | 250 | 122 | 132 | 2.97 | 78 | 236 | 351 |
| 2024 | 80 | -83 | -65 | -1.13 | -15 | 300 | 393 |
| 2025 | 40 | -132 | -120 | -2.04 | -132 | 196 | 252 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Voyager Therapeutics, Inc., ein Biotechnologieunternehmen, konzentriert sich auf die Humangenetik zur Heilung neurologischer Erkrankungen.
| Employees | 141 |
|---|---|
| Headquarters | Lexington, MA |
| Address | 75 Hayden Avenue, 02421 Lexington, United States |
| Phone | 857 259 5340 |
| Website | voyagertherapeutics.com |
| IPO Date | 11. Nov 2015 |
| ISIN | US92915B1061 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Alfred W. Sandrock Jr., M.D., Ph.D. | President, CEO & Director | 1958 |
| Robin Swartz | Principal Financial Officer, Treasurer, Chief Business Officer & COO | 1971 |
| Krystof Bankiewicz M.D., Ph.D. | Founder | – |
| Mark A. Kay M.D., Ph.D. | Founder | 1959 |
| Amy Quinlan | Principal Accounting Officer | 1975 |
| Todd Carter Ph.D. | Chief Scientific Officer | 1970 |
| Gregory Shiferman | Senior VP, General Counsel & Secretary | 1985 |
| Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the CEO | 1977 |
| Mathieu Nonnenmacher Ph.D. | Vice President of Gene Therapy | – |
| Mihalis Kariolis | Vice President of Non-Viral Therapeutics | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.